PVI
VRCA icon

Pura Vida Investments’s Verrica Pharmaceuticals VRCA Stock Holding History

Pura Vida Investments’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,392
Closed -$521K – 125
2018
Q4 		$521K Buy
6,392
+4,392
+220% +$533K 0.1% 63
2018
Q3 		$325K Buy
+2,000
New +$342K 0.07% 104

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CI
Conning Inc Hartford, Connecticut $3.01B AUM 16.23% 1-Year Est. Return

Pura Vida Investments's VRCA Position: Q1 2019 in Review

Pura Vida Investments sold out of Verrica Pharmaceuticals (VRCA) in Q1 2019, closing a stake of 6,392 shares — an estimated $521K sold.

Pura Vida Investments first reported a position in VRCA in Q3 2018 and held it in 2 quarters. The position peaked at $521K in Q4 2018. 40 funds tracked by Wall St. Rank hold VRCA as of Q1 2019.

  • Pura Vida Investments reported no remaining Verrica Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Pura Vida Investments sold 6,392 Verrica Pharmaceuticals shares in Q1 2019, an estimated $521K.
  • Pura Vida Investments first reported a position in Verrica Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Pura Vida Investments's Verrica Pharmaceuticals position peaked at $521K in Q4 2018.
  • 40 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2019.

Based on Pura Vida Investments's 13F filing for Q1 2019, filed 14 May 2019.